You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 12, September 28, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Medical News & Perspectives
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Skin Cancer
 •Dermatology
 •Dermatologic Disorders
 •Melanoma
 •Immunology
 •Immunology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Skin Cancer’s Ranks Rise

Immunosuppression to Blame

Tracy Hampton, PhD

JAMA. 2005;294:1476-1480.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Ever-growing numbers of individuals are at increased risk of developing skin cancer, and not just because of sun worship and the pursuit of the perfect tan. More people are susceptible now because of impaired immunity due to immunosuppressive drugs following organ transplantation or for various rheumatologic and dermatologic conditions. Also vulnerable are patients who have compromised immune surveillance due to such conditions as HIV and chronic lymphocytic leukemia (CLL), which increases their risk of developing cancer.

While such individuals present a challenge to physicians, their conditions can help shed light on the mechanisms involved and may therefore provide opportunities for therapeutic innovations.

TRANSPLANT RECIPIENTS

"Skin cancer is the most common malignancy in the posttransplant setting and affects the majority of patients eventually," said Clark Otley, MD, of the Mayo Clinic and Mayo Medical School, in Rochester, Minn, during the annual meeting of the American Academy of Dermatology held . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cutaneous Malignancies Among HIV-Infected Persons
Crum-Cianflone et al.
Arch Intern Med 2009;169:1130-1138.
ABSTRACT | FULL TEXT  

Cutaneous Colocalized Invasive Poorly Differentiated Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma of the Head and Neck Region: A Case Report and Review of the Literature
Peng et al.
Arch Otolaryngol Head Neck Surg 2009;135:606-610.
FULL TEXT  

Decreased Risk of Prostate Cancer after Skin Cancer Diagnosis: A Protective Role of Ultraviolet Radiation?
de Vries et al.
Am J Epidemiol 2007;165:966-972.
ABSTRACT | FULL TEXT  

Azathioprine, UV light, and skin cancer in organ transplant patients--do we have an answer?
Ulrich and Stockfleth
Nephrol Dial Transplant 2007;22:1027-1029.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.